Elanco Animal Health (NYSE:ELAN) Price Target Raised to $30.00

Elanco Animal Health (NYSE:ELAN) had its price objective hoisted by JPMorgan Chase & Co. from $28.00 to $30.00 in a report issued on Thursday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

A number of other equities analysts have also recently commented on ELAN. UBS Group reiterated a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. Piper Sandler upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $24.00 to $30.00 in a report on Thursday, January 22nd. Citigroup assumed coverage on Elanco Animal Health in a report on Wednesday, April 15th. They set a “buy” rating and a $30.00 price target for the company. Wall Street Zen downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 18th. Finally, Morgan Stanley raised their price objective on shares of Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $28.20.

Elanco Animal Health Trading Down 2.0%

Elanco Animal Health stock opened at $23.54 on Thursday. Elanco Animal Health has a 52 week low of $11.92 and a 52 week high of $27.72. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.08 and a current ratio of 2.16. The stock has a market capitalization of $11.75 billion, a P/E ratio of -47.07, a PEG ratio of 2.68 and a beta of 1.69. The stock has a 50-day simple moving average of $23.81 and a 200 day simple moving average of $23.35.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The business had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.28 billion. During the same quarter last year, the company posted $0.37 earnings per share. Elanco Animal Health’s quarterly revenue was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Analysts expect that Elanco Animal Health will post 1.05 earnings per share for the current year.

Institutional Investors Weigh In On Elanco Animal Health

Hedge funds have recently bought and sold shares of the stock. NewEdge Advisors LLC lifted its position in Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after acquiring an additional 627 shares during the last quarter. Huntington National Bank raised its position in shares of Elanco Animal Health by 136.7% in the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after buying an additional 1,087 shares in the last quarter. Root Financial Partners LLC raised its position in shares of Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after buying an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. acquired a new stake in shares of Elanco Animal Health in the fourth quarter valued at approximately $41,000. Finally, Whittier Trust Co. of Nevada Inc. raised its position in shares of Elanco Animal Health by 80.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after buying an additional 900 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health News Roundup

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Elanco reported Q1 2026 sales that beat expectations, highlighting better-than-expected demand and execution. Elanco’s (NYSE:ELAN) Q1 CY2026 Sales Beat Estimates
• Positive Sentiment: The company raised full-year guidance, now targeting 5%-7% organic growth and adjusted EPS of $1.03-$1.09, suggesting management is more confident in the business momentum. Elanco outlines 5%-7% organic growth and $1.03-$1.09 adjusted EPS as innovation target rises to $1.2B
• Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan and Citi both raising price targets and keeping bullish ratings, which can support sentiment around the stock. Benzinga report on analyst price target increases
• Neutral Sentiment: Elanco’s earnings call and presentation may provide additional detail on the company’s innovation strategy and margin outlook, but the main market driver is the stronger sales and guidance update. Elanco Animal Health Incorporated (ELAN) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Media coverage and CEO interview content reinforce the upbeat earnings narrative, but are unlikely to be the primary stock-moving catalysts. Bloomberg Businessweek Daily: Elanco CEO Jeff Simmons

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.